高级检索
当前位置: 首页 > 详情页

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing

文献详情

资源类型:
Pubmed体系:
机构: [1]Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, [2]The First Affiliated Hospital, Hainan Medical University, Haikou, China, [3]State Key Laboratory of MedicalMolecular Biology, Department of Molecular Biology and Biochemistry, Institute of BasicMedical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, [4]Department of Cellular and Molecular Biology, Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing, China, [5]Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China, [6]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China, [7]Department of Surgery, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany, [8]Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia
出处:
ISSN:

关键词: CRISPR/Cas9 gene editing technology anti-cancer therapy off-target effect ethics

摘要:
Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials.Copyright © 2022 Chen, Guo, Zhao, Xu, Song, Yu, Pilarsky, Nainu, Li, Zhou and Zhang.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
第一作者:
第一作者机构: [1]Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, [2]The First Affiliated Hospital, Hainan Medical University, Haikou, China,
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号